Abstract. SSH-BM-I was synthesized from tryptamine by using a newly developed synthetic method, and it has structural similarity to bromomelatonin. Recently, it had been reported that SSH-BM-I increases osteoblasts in scales of gold fish. However, the effect of SSH-BM-I on osteoblast differentiation in mammalian cells has not yet been examined. Therefore, this study examined the effect of SSH-BM-I on osteoblast differentiation in mesenchymal progenitor-like cells and mature osteoblast-like cells. SSH-BM-I enhanced terminal osteoblast differentiation, as indicated by mineralization, which was accompanied by upregulation of the osteogenic marker genes bone sialoprotein (BSP) and osteocalcin (OC). However, in mesenchymal progenitor ROB-C26 cultures, no mineralized nodules were observed regardless of SSH-BM-I treatment, although BMP-2 was able to induce nodule formation in these cells. Furthermore, BMP-2-induced nodule formation was suppressed by SSH-BM-I treatment in ROB-C26 cultures. We further investigated the impact of the timing and duration of SSH-BM-I treatment on osteoblast differentiation. The effect of SSH-BM-I treatment on osteoblast differentiation of ROB-C26 in the presence of BMP-2 switches from negative to positive sometime between day 6 and 9, because SSH-BM-I treatment enhanced the formation of mineralized nodules when it was started on day 9, but suppressed nodule formation when it was started at day 6 or earlier. These results suggest that the stimulatory effects of SSH-BM-I on the formation of mineralized nodules depend on the degree of cell differentiation.
Introduction
SSH-BM-I was synthesized from tryptamine as a novel compound as part of an effort to develop drugs for the treatment of both erectile dysfunction and baldness by using a newly developed synthetic method, and this drug has structural similarity to the bromomelatonin ( Fig. 1) (1, 2). The chemical structure of SSH-BM-I is 1-benzyl-2,4,6-tribromomelatonin (Fig. 1) . SSH-BM-I is named after the initials of its inventors and its biological function: Somei, Suzuki, Hattori, Bone Metabolism. Recently, it had been reported that SSH-BM-I up-regulated osteoblast differentiation in scales of gold fishes (3) . However, the effect of SSH-BM-I on osteoblast differentiation in mammalian cells has not yet been examined. Therefore, this study examined the effect of SSH-BM-I on osteoblast differentiation in mesenchymal progenitor-like cells and mature osteoblast-like cells.
Mesenchymal cells differentiate into several specialized cell types, including osteoblasts and adipocytes (4 -6) . The developmental process from the mesenchymal progenitors to particular cell types can be divided into two stages, commitment and terminal differentiation (7, 8) . This differentiation process is regulated by several cytokines. Bone morphogenetic protein 2 (BMP-2) is one of the most powerful cytokines and it promotes the dif-ferentiation of mesenchymal cells into osteoblasts in vitro and also induces bone formation in vivo (4, 9) .
The study of cell differentiation requires in vitro models using phenotypically stable cultured cell lines, in which direct effects on the individual cell types can be investigated. Therefore, to investigate the effect of SSH-BM-I on osteoblast differentiation, we used two cultured cell lines, ROB-C26 and ROS17/2.8. ROB-C26 is a clonal mesenchymal progenitor-like cell line isolated from newborn rat calvaria. ROB-C26 cells are pre-committed cells and they are capable of differentiating into osteoblastic cells with BMP-2 treatment (10) or into adipocytes with dexamethasone (Dex) treatment (6) . ROS17/2.8 cells are rat osteoblast-like osteosarcoma cells that have been committed to osteoblasts. ROS17/2.8 cells have the phenotype of mature osteoblasts and are able to form bone-like nodules during terminal osteoblast differentiation (11, 12) .
In this study, SSH-BM-I stimulated terminal osteoblast differentiation in ROS17/2.8 cells, as identified by mineralization, which was accompanied by the up-regulation of the osteogenic marker genes bone sialoprotein and osteocalcin. Conversely, SSH-BM-I suppressed BMP-2-induced osteoblast differentiation in ROB-C26 cells.
Materials and Methods

Cell culture and reagents
The cells were pre-cultured in 12-well plates until they reached confluence in the growth media consisting of α-MEM, 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin. Subsequently, the cells were cultured for the indicated periods under the indicated culture condition in the media supplemented with 50 μg/ml Lascorbate phosphate (Sigma, St. Louis, MO, USA), and 10 mM β-glycerophosphate (Sigma) (osteogenic medium). The culture medium was changed every 2 days. The antibiotics and cell culture media were obtained from Gibco (Grand Island, NY, USA) or Wako Chemicals (Osaka), respectively. FBS was purchased from Japan Bioserum Co., Ltd. (Tokyo). Dex and rhBMP-2 were acquired from Sigma and R&D Systems (Minneapolis, MN, USA), respectively. SSH-BM-I was synthesized according to a previously described method (1). SSH-BM-I was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 −3 M, which was then diluted in culture medium to obtain the desired working concentration.
Alizarin Red S staining
The cells cultured under the indicated conditions in the osteogenic medium were rinsed twice and fixed in 4% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.3) for 30 min. Subsequently, Alizarin Red S solution was added. Following a 10-min incubation, the plates were washed with distilled water and visualized under a light microscope.
Ca
2+ release assay Cells were cultured under the indicated conditions in the osteogenic medium. After removing the supernatant, the cells were washed with 10 mM Tris-HCl (pH 7.2). HCl (1 N) was added to each well and allowed to dry completely at room temperature. Twenty microliters of distilled water was then added to each well, and the amount of Ca 2+ was determined using the Calcium E-test (Wako Chemicals) according to the manufacturer's instructions. Oil Red O staining ROB-C26 cells were cultured under the indicated conditions in the osteogenic medium. The adipocyte-like cells were identified using Oil Red O to stain cytoplasmic lipid droplets in the cells. Oil Red O (0.5 g) was dissolved in 100 ml of isopropanol, diluted 3:2 with distilled water, and filtered through a Whatmann #1 filter before use. ROB-C26 cell cultures were fixed with 10% formalin for 30 min, stained with Oil Red O for 1 h, rinsed repeatedly with distilled water to remove residual stain, and examined with a light microscope.
Alkaline phosphatase (ALP) staining
Confluent cells were cultured for the indicated times in the presence or absence of the indicated concentrations of SSH-BM-I and BMP-2 in the osteogenic medium. The cultures were washed twice with PBS, fixed with 4% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.2) for 30 min, washed twice with buffer, and stained with ALP staining solution at pH 9.5 (NBT/BCIP ready-to-use tablets; Roche Diagnostics, Penzberg, Germany). The cultures were washed and then analyzed with an EPSON scanner, GT-X800.
Measurement of ALP activity
Alkaline phosphatase activity was measured using pnitrophenyl phosphate. Briefly, cells were cultured under the indicated conditions in the osteogenic medium. After washing with Ca/Mg-free PBS, the cells were collected into Ca/Mg-free PBS and sonicated. The cell lysates were centrifuged, the supernatant was collected, and aliquots of supernatant were mixed with AMP buffer (56 mM 2-amino-2-methyl-1-propanol, 1 mM MgCl 2 , and 10 mM p-nitrophenyl phosphate). The reaction mixture was incubated at 37°C for 30 min, 0.2 N NaOH was added to stop the reaction, and the absorbance at 410 nm was measured. ALP activity is expressed as p-nitrophenol production per ng of total protein. Protein concentration was determined using the Bio-Rad protein assay reagent, with bovine serum albumin (BSA) as the standard.
Luciferase assay of (OSE2)x6-Luc construct
A construct containing six repeats of the Runx2 binding site upstream of the OC promoter and fused to firefly luciferase [(OSE2)x6-Luc] was kindly provided by Dr. Gerard Karsenty (College of Physicians and Surgeons, Columbia University, New York, NY, USA). A plasmid containing firefly luciferase but lacking promoter sequences, pGL3-Basic (Promega, Madison, WI, USA), was also used as a negative control. ROS17/2.8 cells were seeded on a 6-well plate at 90% confluence and then were incubated for 18 h. (OSE2) x6-Luc or pGL3-Basic (2 μg) was transfected in the cells using a lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA). At 48 h after transfection, cells were cultured with or without SSH-BM-I for an additional 24 h in the osteogenic medium and then rinsed with PBS and scraped with lysis buffer. Luciferase activity was measured using a Dual Luciferase Assay Kit (Promega) according to the manufacturer's instructions. The experiments were performed in triplicate, and the values of firefly luciferase activity of the (OSE2)x6-Luc and pGL3-Basic were normalized against values obtained for renilla luciferase activity, as an internal control.
Real time RT-PCR analysis
Cells were cultured under the indicated conditions in the osteogenic medium, and then real-time RT-PCR was performed. First-strand cDNA was synthesized from 1 μg of DNase I-treated total RNA in 20 μl of a solution containing 1x first-strand buffer, 50 ng random primer, 10 mM dNTP mixture, 1 mM DTT, and 0.5 units Super Script III reverse transcriptase (Invitrogen) at 42°C for 1 h. Subsequently, cDNA was diluted 5-fold in sterile distilled water and a 2 μl aliquot of the diluted cDNA was subjected to real-time RT-PCR using SYBR Green I dye (Takara, Tokyo). Real-time RT-PCR was performed in a 25 μl solution containing 1 × PCR buffer, 1.5 mM dNTP mixture, 1 × SYBR Green I, 15 mM Mg 2+ solution, 0.25 units Ex Taq R-PCR (Takara), and 20 μM primers (sense and anti-sense). Assays were performed on a Smart Cycler and analyzed with the accompanying Smart Cycler software (Ver. 1.2 d). The cycling conditions were 40 cycles of 95°C for 3 s and 68°C for 20 s, and measurements commenced at the end of the annealing step (68°C). Sense and antisense primers used were as follows: bone sialoprotein (BSP) (forward, 5'-GAT AGT TCG GAG GAG GAG GG-3′; reverse, 5′-ACT CCA ACT TTC CAG CGT-3′), osteocalcin (OC) (forward, 5′-GAA CAG ACA AGT CCC ACA C-3′; reverse, 5′-GAG CTC ACA CAC CTC CCT G-3′), Runx2 (forward, 5′-ACA ACC ACA GAA CCA CAA G-3′; reverse, 5′-TCT CGG TGG CTG GTA GTG A-3′), OSX (forward, 5′-CTT TCC CCA CTC ATT TCC TG-3′; reverse, 5′-CTA GGC AGG CAG TCA GAA G-3′), β-actin (forward, 5′-CTT TCT ACA ATG AGC TGC GTG-3′; reverse-3′, 5′-ATG GCT GGG GTG TTG AAG G-3′). The mRNA expression of all transcripts analyzed was normalized against that of β-actin.
Western blot analysis
Cells were cultured under the indicated conditions in the osteogenic medium, and then western blot analysis was performed. Cells were lysed with 1 × lysis buffer containing 20 mM HEPES, pH 7.6, 350 mM NaCl, 50 mM KCl, 1 mM DTT, 0.25% nonidet P-40, 5 mM NaF, 1 mM EDTA, 5 mM MgCl 2 , 0.25 mM phenylmethylsulfonyl fluoride, 10% glycerol, and 1 mM sodium orthovanadate. Ten micrograms of protein was separated by SDS-PAGE and transferred to nitrocellulose membranes at 4°C for 1 h. Membranes were blocked overnight with Tris-buffered saline (pH 7.4) containing 2% BSA and 0.1% Tween 20 and were then incubated in the presence of 1:500 dilutions of the primary antibodies. After washing with PBS, the membranes were incubated with secondary antibodies for 1 h. After final washing with PBS, bands were visualized by chemiluminescence using an ECL kit (GE Healthcare Japan, Tokyo) according to the manufacturer's instructions. The antibody used for western blotting against actin (sc-1615) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and the antibody against phosphorylated Smad1/5/8 (#9511) was obtained from Cell Signaling Technology (Beverly, MA, USA). An actin-specific antibody was used as the internal control.
Statistical analysis
Results are presented as the mean ± S.D. of triplicate cultures and differences were assessed using the Student's t-test. Significant differences (P < 0.05) are indicated by marks.
Results
SSH-BM-I stimulated mineralization in ROS17/2.8 cells
To examine the effect of SSH-BM-I on mineralization, ROS17/2.8 cells were cultured with SSH-BM-I or DMSO (vehicle) for the indicated number of days, and then alizarin red S staining was performed. Alizarin red S staining revealed that the mineralization in the SSH-BM-I-treated cultures was accelerated as compared with that of the vehicle-treated cultures at day 6 ( Fig. 2A) . The amount of Ca 2+ released from the mineralization nodules was also determined for the SSH-BM-I-treated and the vehicle-treated cultures (Fig. 2B) . The result of Alizarin red S staining was consistent with the Ca 2+ levels. The Ca 2+ levels increased significantly, by approximately 2-fold, at day 6 in the SSH-BM-I-treated cultures, as compared to the vehicle-treated cultures (Fig. 2B) .
SSH-BM-I upregulated the mRNA levels of BSP and OC in ROS17/2.8cells
To determine whether SSH-BM-I affected the mRNA expression of osteogenic genes in ROS17/2.8 cells, the ROS17/2.8 cells were cultured in the presence or absence of SSH-BM-I for the indicated number of days, and then the mRNA expression levels of BSP and OC were analyzed by real-time RT-PCR. SSH-BM-I increased the mRNA expression levels of BSP and OC as compared to the vehicle-treated cells at day 6 (Fig. 3A) . As Runx2 and Osterix (OSX), transcription factors related to osteoblast differentiation, up-regulate mRNA expression of BSP and OC (13 -15), we examined whether SSH-BM-I was capable of affecting the expression of these transcription factors and transcriptional activity of Runx2 in ROS17/2.8 cells. No significant difference in Runx2 and OSX mRNA expression was observed between SSH-BM-Itreated cells and vehicle-treated cells throughout the culture time period (Fig. 3A) . Next, to examine the transcriptional activity of Runx2, a luciferase assay was performed using the (OSE2)x6-Luc construct, which contains six repeats of the Runx2 binding site (OSE2) (13) , fused upstream of the minimal 34-bp OC promoter. The luciferase assay showed no difference in Runx2-driven promoter activity between the SSH-BM-I-treated cells and the vehicle-treated cells (Fig. 3B) .
We further investigated whether SSH-BM-I affects the phosphorylation of Smad1,5,8 because the phosphorylated Smads are well known as a regulator for the transcription of osteogenic genes. Expression levels of phosphorylated Smad1,5,8 in SSH-BM-I-treated cells were similar to that in the vehicle-treated cells throughout the culture time periods (Fig. 3C) . 
SSH-BM-1 exhibited different effects on osteoblast differentiation depending on the duration of BMP-2 pretreatment
Our data showed that SSH-BM-I stimulates mineralization in mature osteoblasts (ROS17/2.8 cells). Therefore, we next investigated whether SSH-BM-I was capable of inducing the cellular differentiation of mesenchymal progenitor cells into osteoblasts. ROB-C26 cells, pre-committed stem cells, were cultured with SSH-BM-I or the vehicle control for 24 days, and then Alizarin red S staining was performed. As a positive control, cells were treated with BMP-2, which is known to induce the differentiation of mesenchymal cells into osteoblasts (10) . No Alizarin Red S-positive nodules were observed in the SSH-BM-I-treated culture or in the vehicle-treated cultures, although the BMP-2-treated cultures were strongly stained with Alizarin red S (Fig. 4A) .
We further investigated the effect of SSH-BM-I on the osteoblast differentiation in ROB-C26 cells by performing the SSH-BM-I treatment beginning on several different culture days. SSH-BM-I treatment was commenced on day 0, 3, 6, or 9 in cells that were cultured in the presence of BMP-2. As a control, cells were cultured in presence of BMP-2 alone. After 24 days of culture, the cells were stained with Alizarin Red S. Surprisingly, when SSH-BM-I treatment was applied from day 0 to day 6 in the presence of BMP-2, Alizarin red S-positive mineralized nodules were decreased as compared to the culture treated with BMP-2 alone. By contrast, the formation of mineralized nodules in BMP-2-treated cultures was significantly accelerated when SSH-BM-I, treatment was started on day 9, as compared to cultures treated with BMP-2 alone (Fig. 4B) . These results were consistent with the results of calcium deposition (Fig. 4C) . We further examined the mRNA expression of osteogenic markers that corresponded to the periods of SSH-BM-I treatment in the presence of BMP-2 shown in Fig.  4 . C26 cells were cultured in the presence of BMP-2, and SSH-BM-I treatments were commenced at the time points indicated in Fig. 4 . After 24 days of culture, realtime RT-PCR was performed.
SSH-BM-I treatment commencing on days 0, 3, and 6 significantly inhibited BMP-2-induced OC, BSP, and OSX mRNA (Fig. 5A) . In contrast, Dex treatment commencing on day 9 or 12 increased OC and BSP mRNA expression compared to that of BMP-2 treatment alone. In addition, Dex treatment commencing on day 9 or 12 had no effect on BMP-2-induced OSX mRNA expression (Fig. 5A) .
As BMP-2 exerts its effects through phosphorylation of receptor-Smads (R-Smads), including Smad1, 5, and 8 (16), we next examined whether SSH-BM-I affects the Smad signaling activated by BMP-2. ROB-C26 cells were cultured with or without SSH-BM-I in the presence of BMP-2 for the indicated times. After culture, western blotting using antibody against phosphorylated Smad1/5/8 was performed. No difference was observed in the phosphorylated Smad1/5/8 (P-Smads) expression level between the BMP-2-and BMP-2 + SSH-BM-Itreated cells (Fig. 5B) .
Our results described above indicate that SSH-BM-I treatment commencing on days 0 -6 inhibited mineralization. By contrast, mineralization was enhanced by SSH-BM-I treatment commencing on day 9 in the presence of BMP-2. These differences in the effects of SSH-BM-I treatment prompted us to study the expression and activity of alkaline phosphatase (ALP, a common marker of osteoblast differentiation) in ROB-C26 cells in the presence of BMP-2. Low levels of ALP activity were detectable in days 0 -6. ALP activity was markedly increased on day 9 in the presence of BMP-2, which corresponded to the onset of the positive effect of SSH-BM-I on mineralization (Fig. 6: A and B) .
Because ALP activity markedly increased between day 6 and day 9, we hypothesized that ROB-C26 cells were committed into osteoblasts in this period. Therefore, to investigate this hypothesis, we examined whether the cells at day 6 and day 9 have the ability to differentiate into adipocytes by treatment with dexamethasone. Cells were cultured with Dex beginning on day 6 or day 9 in the presence of BMP-2. As positive control for adipocyte differentiation, cells were cultured with Dex beginning on day 0 in the absence of BMP-2. When Dex treatment was started on day 6, cells formed lipid droplets identified by Oil Red O staining, indicating the cells had differentiated into adipocytes (Fig. 6C) . On the other hand, lipid droplets were scarcely observed in the cells cultured with Dex beginning on day 9 (Fig. 6C) .
Discussion
We have demonstrated that SSH-BM-I promotes the formation of mineralized bone-like nodules in osteoblasts in a cell differentiation stage-dependent manner.
First, we investigated the effects of SSH-BM-I on the formation of mineralized nodules. Increased mineralized nodule formation by SSH-BM-I treatment was observed in mature osteoblast ROS17/2.8 cultures. However, in mesenchymal progenitor ROB-C26 cultures, no mineralized nodules were observed regardless of SSH-BM-I treatment, although BMP-2 was able to induce nodule formation in these cells. Furthermore, BMP-2-induced nodule formation was suppressed by SSH-BM-I treatment in ROB-C26 cultures. These results suggest that the stimulatory effects of SSH-BM-I on the formation of mineralized nodules depend on the degree of cell differentiation.
The development of mesenchymal progenitors into particular cell types can be divided into two stages, commitment and terminal differentiation (7, 8) . ROS17/2.8 cells already have been committed to becoming osteoblasts and are able to form mineralized nodules during terminal osteoblast differentiation (11, 12) . By contrast, ROB-C26 cells are pre-commitment cells (6) , which require commitment to the osteoblast lineage prior to the formation of mineralized nodules. On the basis of this evidence, we hypothesized that SSH-BM-I facilitates the formation of mineralized nodules in terminal osteoblast differentiation, but is unable to commit progenitor cells to becoming osteoblasts or to inhibit the commitment to the osteoblast lineage. To confirm this hypothesis, we investigated the impact of the timing and duration of SSH-BM-I treatment on osteoblast differentiation. The effect of SSH-BM-I treatment on osteoblast differentiation of ROB-C26 in the presence of BMP-2 switches from negative to positive sometime between day 6 and 9, because SSH-BM-I treatment enhanced the formation of mineralized nodules when it was started on day 9, but suppressed nodule formation when it was started at day 6 or earlier. In addition, ALP activity significantly increased between day 6 and day 9. Furthermore, Dex treatment beginning on day 6 induced adipocyte differentiation in the presence of BMP-2, but Dex treatment beginning on day 9 failed to induce adipocyte differentia- tion. These results suggest that ROB-C26 were committed into osteoblasts between days 6 and 9 by BMP-2 treatment and strongly support the hypothesis described above.
We further attempted to determine whether SSH-BM-I affected the expression of osteogenic genes in ROS17/2.8 cells. The results of real-time PCR showed that mRNA expression of BSP and OC were increased in SSH-BM-I-treated cells on day 6. However, these expression levels were not changed on day 1 of SSH-BM-I treatment. This may indicate that SSH-BM-I regulates BSP and OC expression indirectly. The expression of osteoblast marker genes, including BSP and OC, is regulated by Runx2 and OSX (13 -15) . However, SSH-BM-I failed to regulate the expression of these transcription factors and of transcriptional activity of Runx2 in ROS17/2.8 cells. Therefore, we believe that SSH-BM-I increases BSP and OC expression in a Runx2-independent manner, which is followed by the formation of mineralized nodules. For example, the Wnt-beta catenin signaling pathway also plays a pivotal role in osteoblast differentiation (17) . Therefore, investigation of the effects of the treatment of SSH-BM-I on this signaling cascade may provide important information to resolve the mechanism by which SSH-BM-I regulates osteoblast differentiation. On the other hand, in ROB-C26 cells, SSH-BM-I treatment commenced on day 0 -6 decreased BMP-2-induced OSX expression, which was consistent with the inhibition of mineralization. However, no effect of SSH-BM-I treatment on BMP-2-induced phosphorylation of Smads was observed. These results may suggest that suppression of BMP-2-induced OSX expression was caused in a BMP-2/Smads signaling independent manner, which may result in that SSH-BM-I inhibited osteoblast differentiation of ROB-C26 cells.
Melatonin is a synthetic intermediate for SSH-BM-I (1) and its chemical structure is similar to that of SSH-BM-I. It has been reported that melatonin is involved in the regulation of calcium homeostasis and bone metabolism (18) . This seems to suggest that melatonin and SSH-BM-I regulate osteoblast differentiation and osteogenesis via a common receptor. However, one recent report demonstrated that SSH-BM-type compounds activated osteoblasts, while melatonin suppressed osteoblastic activity at the same incubation time in the scales of goldfish (3) . On the basis of this evidence, it seems that another receptor for SSH-BM-I exists in osteoblasts. SSH-BM-I derivatives might bind to this receptor and regulate osteogenesis. In fact, a different mechanism of action of melatonin and melatonin-related substances has been reported (19 -21) .
As another possibility for the molecular mechanism by which SSH-BM-I regulates osteoblast differentiation, cyclic AMP signaling may play an important role. SSH-BM-I is synthesized from tryptamine as shown in Fig. 1 . Tryptamine is one of the trace amines (22, 23) . A family of G protein-coupled receptors (GPCRs) has been reported as a trace amine-associated receptor (TAAR1) (24) . Some amines derived from thyroid hormone decarboxylation and deiodination, known as thyronamines, have been shown to be endogenous compounds that stimulate cAMP production via the activation of TAAR1 (24) . Cyclic AMP signaling regulates osteogenic events including OSX transcription (25, 26) . For example, parathyroid hormone (PTH) regulates the osterix expression predominantly through cAMP-dependent protein kinase A (PKA) signaling in osteoblast-like cells (27) and the overexpression of PKA inhibitor γ (PKIγ) suppressed the OSX expression in C2C12 cells (34) . In addition, SST-VEDI-1, which is also a tryptamine derivative and has a similar chemical structure to that of SSH-BM-I, regulates cAMP level (28) . Based on the findings of these reports, it is therefore possible that the cAMPdependent signaling pathway via TAAR1 may act on the SSH-BM-I-mediated osteoblast differentiation.
Previously, SSH-BM-I have been demonstrated to stimulate osteoblast activity in cultured scales of goldfish (3) . The teleost scale is a calcified tissue that contains osteoclasts and osteoblasts (29, 30) . Bone matrix components, including type I collagen, osteonectin, and OC, are present in these scales as well as in mammalian bone (31 -33) . Hydroxyapatite is also found in scales (34) . Thus, there are many similarities between the teleost scale and mammalian bone. Furthermore, in this study, we found that SSH-BM-I stimulated terminal osteoblast differentiation in rat osteoblasts. On the basis of these evidences, SSH-BM-I has the potential to increase bone mineral density and may have utility for use as a drug for bone diseases such as osteoporosis.
In conclusion, SSH-BM-I enhanced terminal osteoblast differentiation, as indicated by mineralization, which was accompanied by upregulation of the osteogenic marker genes BSP and OC. On the other hand, SSH-BM-I inhibited osteogenesis of pre-committed progenitor ROB-C26 cells. Our studies have characterized the activity of SSH-BM-I and suggest that SSH-BM-I is an important target for future studies on osteoblast differentiation.
